Embracing Imatinib: a novel approach to safeguarding the endothelial barrier in patients with COVID-19
Abstract Imatinib, an ABL tyrosine-kinase inhibitor, shows promise in restoring endothelial barrier function in patients with COVID-19, thus, preventing cytokine leakage from the alveolar compartment to the systemic compartment. COVID-19 is characterized by an alveolar cytokine storm, and imatinib has been shown to strengthen the endothelial barrier and mitigate alveolar inflammatory responses by modulating NF-κB signaling. Incorporating imatinib into COVID-19 treatment strategies offers a novel approach to safeguard the endothelial barrier and address the complex pathophysiology of the disease, including its potential implications in long COVID. Given that endothelial dysfunction plays a central role in COVID-19 progression and long COVID development, protecting the endothelial barrier during acute infection is crucial in preventing the persistent endothelial dysfunction associated with long COVID..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:26 |
|---|---|
| Enthalten in: |
Angiogenesis - 26(2023), 4 vom: 02. Aug., Seite 481-483 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kow, Chia Siang [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer Nature B.V. 2023 |
|---|
| doi: |
10.1007/s10456-023-09889-2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR053246926 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR053246926 | ||
| 003 | DE-627 | ||
| 005 | 20231002150210.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231002s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10456-023-09889-2 |2 doi | |
| 035 | |a (DE-627)SPR053246926 | ||
| 035 | |a (SPR)s10456-023-09889-2-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kow, Chia Siang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Embracing Imatinib: a novel approach to safeguarding the endothelial barrier in patients with COVID-19 |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer Nature B.V. 2023 | ||
| 520 | |a Abstract Imatinib, an ABL tyrosine-kinase inhibitor, shows promise in restoring endothelial barrier function in patients with COVID-19, thus, preventing cytokine leakage from the alveolar compartment to the systemic compartment. COVID-19 is characterized by an alveolar cytokine storm, and imatinib has been shown to strengthen the endothelial barrier and mitigate alveolar inflammatory responses by modulating NF-κB signaling. Incorporating imatinib into COVID-19 treatment strategies offers a novel approach to safeguard the endothelial barrier and address the complex pathophysiology of the disease, including its potential implications in long COVID. Given that endothelial dysfunction plays a central role in COVID-19 progression and long COVID development, protecting the endothelial barrier during acute infection is crucial in preventing the persistent endothelial dysfunction associated with long COVID. | ||
| 700 | 1 | |a Ramachandram, Dinesh Sangarran |4 aut | |
| 700 | 1 | |a Hasan, Syed Shahzad |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Angiogenesis |d Dordrecht [u.a.] : Springer Science + Business Media B.V, 1997 |g 26(2023), 4 vom: 02. Aug., Seite 481-483 |w (DE-627)SPR010159355 |w (DE-600)2003393-X |x 1573-7209 |7 nnns |
| 773 | 1 | 8 | |g volume:26 |g year:2023 |g number:4 |g day:02 |g month:08 |g pages:481-483 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s10456-023-09889-2 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 26 |j 2023 |e 4 |b 02 |c 08 |h 481-483 | ||